GRAIL vs Mirum Pharmaceuticals
GRAIL (GRAL), health care, and Mirum Pharmaceuticals (MIRM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Mirum Pharmaceuticals is worth $6B on the stock market and GRAIL $4.8B: Mirum Pharmaceuticals is valued at 26% more. GRAIL's operating margin in its latest fiscal year was -382% and Mirum Pharmaceuticals's -4.25%. Over the past year GRAIL's share price has moved +29.6% and Mirum Pharmaceuticals's +26.9%.
Key facts
- GRAIL market value
- $4.8B
- Mirum Pharmaceuticals market value
- $6B
- GRAIL revenue
- $147.2MFY to 2025-12-31
- Mirum Pharmaceuticals revenue
- $521.3MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | GRAIL | Mirum Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.8Blower | $6Bhigher |
| Revenue | $147.2Mlower | $521.3Mhigher |
| Earnings | -$408.4Mlower | -$23.4Mhigher |
| Employees | 910higher | 470lower |
| Total assets | $2.9Bhigher | $842.8Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 32.3higher | 11.5lower |
| P/B | 1.9 | — |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -382%lower | -4.25%higher |
| Balance sheet | ||
| Net assets | $2.6Bhigher | $314.7Mlower |
| Total liabilities | $344.2Mlower | $528.1Mhigher |
| Total debt | — | — |
| Cash on hand | $249.7Mlower | $296.7Mhigher |
| Price change | ||
| Today | +0.27%lower | +0.40%higher |
| 1 year | +29.6%higher | +26.9%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Julian and Felix Baker1.4% / 0.3%
GRAIL only (2)
- Andrew Spokes3.0%
- Primecap team0.2%
Mirum Pharmaceuticals only (2)
- Peter Kolchinsky0.3%
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": GRAIL / Mirum Pharmaceuticals). Who owns GRAL · Who owns MIRM
More on GRAIL
Further comparisons
GRAIL against its closest peers
Mirum Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, GRAIL or Mirum Pharmaceuticals?
By market value, Mirum Pharmaceuticals is the larger: $6B against $4.8B for GRAIL. By revenue in its latest fiscal year, Mirum Pharmaceuticals is the larger: $521.3M against $147.2M for GRAIL.
Which has the higher operating margin?
Mirum Pharmaceuticals: -4.25%, against -382% for GRAIL. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both GRAIL and Mirum Pharmaceuticals?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “GRAIL vs Mirum Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/gral-vs-mirm
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.